Search results for " alzheimer"

showing 10 items of 149 documents

Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: a meta-analysis of longitudinal studies.

2019

Objective: To synthesize the evidence across longitudinal studies comparing survival in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Methods: We conducted a systematic review and meta-analysis of studies comparing survival in clinically diagnosed DLB to AD. Longitudinal cohort studies were identified through a systematic search of major electronic databases from inception to May 2018. A random effects meta-analysis was performed to calculate survival time and relative risk of death. Results: Overall, 11 studies were identified including 22,952 patients with dementia: 2029 with DLB (mean diagnosis age 76.3; 47% female) compared with 20,923 with AD (mean diagnosis age 77.2; 6…

Lewy Body DiseaseMale0301 basic medicineAgingmedicine.medical_specialtyDiseaseBiochemistryLewy bodie03 medical and health sciences0302 clinical medicineA meta-analysis of longitudinal studies.- Ageing research reviews cilt.50 ss.72-80 2019 [MUELLER C. Soysal P. RONGVE A. ISIK A. THOMPSON T. MAGGI S. SMITH L. Basso C. STEWART R. BALLARD C. et al. -Survival time and differences between dementia with Lewy bodies and Alzheimer-s disease following diagnosis]Alzheimer DiseaseInternal medicinemental disordersmedicineHumansDementiaLongitudinal StudiesLongitudinal cohortMortalityMolecular BiologyAgedDementia with Lewy bodiesbusiness.industryCognitive scoreAlzheimer's diseaseRandom effects modelmedicine.diseaseSurvival RateObservational Studies as Topic030104 developmental biologyNeurologyMeta-analysisRelative riskFemaleDementiabusinessLewy bodiesAlzheimer’s disease030217 neurology & neurosurgeryBiotechnology
researchProduct

Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types.

2008

Objective:  i) to describe the neuropsychiatric profile of elderly subjects with dementia by comparing vascular (VaD) and degenerative dementias, i.e. dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD); ii) to assess whether the severity and type of dementia are associated with clinically relevant neuropsychiatric symptoms (CR-NPS). Method:  One hundred and thirty-one out-patients with VaD, 100 with DLB and 690 with AD were studied. NPS were evaluated by the neuropsychiatric inventory (NPI). Results:  Vascular dementia had lower total and domain-specific NPI scores and a lower frequency of CR-NPS than AD and DLB, for which frequency of CR-NPS increased significantly with disease s…

Lewy Body DiseaseMalemedicine.medical_specialtyPathologyPsychometricsDiseaseNeuropsychological TestsCentral nervous system diseaseDegenerative diseaseAlzheimer DiseaseInternal medicinemental disordersmedicineDementiaHumansVascular dementiaAgedAged 80 and overLewy bodyDementia with Lewy bodiesDementia Vasculartechnology industry and agricultureReproducibility of Resultsneuropsychiatric symptoms vascular dementia dementia with Lewy bodies Alzheimer’s disease dementia severitymedicine.diseasePsychiatry and Mental healthnervous systemDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer's diseasePsychologyActa psychiatrica Scandinavica
researchProduct

The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design

2017

Dementia with Lewy bodies (DLB) causes elevated outlays for the National Health Systems due to high institutionalization rate and patients' reduced quality of life and high mortality. Furthermore, DLB is often misdiagnosed as Alzheimer's disease. These data motivate harmonized multicenter longitudinal cohort studies to improve clinical management and therapy monitoring. The Italian DLB study group of the Italian Neurological Society for dementia (SINdem) developed and emailed a semi-structured questionnaire to 572 national dementia centers (from primary to tertiary) to prepare an Italian large longitudinal cohort. The questionnaire surveyed: (1) prevalence and incidence of DLB; (2) clinical…

Lewy Body Diseasemedicine.medical_specialtyPediatricsDementia with Lewy bodieDementia with Lewy bodiesDermatologyCohort StudiesDiagnosis Differential03 medical and health sciences0302 clinical medicineQuality of lifeAlzheimer DiseaseSurveys and Questionnairesmental disordersStandardization of diagnostic proceduresDiagnosisDementia with Lewy bodies; Standardization of diagnostic procedures; Survey; Alzheimer Disease; Cohort Studies; Diagnosis Differential; Disease Management; Humans; Italy; Lewy Body Disease; Research Design; Surveys and Questionnaires; 2708; Neurology (clinical); Psychiatry and Mental HealthmedicineDementiaHumans030212 general & internal medicineSurveyMED/01 - STATISTICA MEDICAMED/26 - NEUROLOGIAbusiness.industryDementia with Lewy bodiesDisease ManagementStandardization of diagnostic procedureGeneral Medicinemedicine.diseaseSettore MED/26 - NEUROLOGIADementia with Lewy bodies; Standardization of diagnostic procedures; Survey; 2708; Neurology (clinical); Psychiatry and Mental HealthItalyResearch DesignPsychiatry and Mental HealthCohortDifferentialPhysical therapyDeliriumNeurology (clinical)Alzheimer's diseasemedicine.symptombusiness030217 neurology & neurosurgeryFrontotemporal dementiaCohort study2708
researchProduct

MALATTIA DI ALZHEIMER: PREDISPOSIZIONE, PREVENZIONE E TERAPIE FARMACOLOGICHE

2008

MALATTIA DI ALZHEIMER PREDISPOSIZIONE PREVENZIONE
researchProduct

MALATTIA DI ALZHEIMER: PREDISPOSIZONE, PREVENZIONE E TERAPIE FARMACOLOGICHE

2008

MALATTIA DI ALZHEIMER anziano
researchProduct

STUDIO DI SEGMENTAZIONE MORFOVOLUMETRICA IN PAZIENTI CON DECLINO COGNITIVO LIEVE, MALATTIA DI ALZHEIMER E MALATTIA DI PARKINSON

Magnetic Resonance Imaging (MRI) voxel-based morphometry (VBM) Alzheimer Disease (AD) Parkinson Disease (PD) Mild Cognitive Impairment (MCI)Settore MED/37 - Neuroradiologiarisonanza magnetica (MRI) segmentazione morfovolumetrica (VBM) malattia di Alzheimer (AD) malattia di Parkinson PD) declino cognitivo lieve (MCI)Settore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification.

2019

Background and purpose While AD can be definitively confirmed by postmortem histopathologic examination, in vivo imaging may improve the clinician's ability to identify AD at the earliest stage. The aim of the study was to test the performance of amyloid PET using new processing imaging algorithm for more precise diagnosis of AD. Methods Amyloid PET results using a new processing imaging algorithm (MRI-Less and AAL Atlas) were correlated with clinical, cognitive status, CSF analysis, and other imaging. The regional SUVR using the white matter of cerebellum as reference region and scores from clinical and cognitive tests were used to create ROC curves. Leave-one-out cross-validation was carr…

Male18F-florbetabenAmyloidSensitivity and SpecificityAmyloid-PET Imaging030218 nuclear medicine & medical imagingWhite matter03 medical and health sciences0302 clinical medicineAlzheimer DiseasePositron Emission Tomography Computed Tomographymental disordersStilbenesmedicineImage Processing Computer-AssistedDementiaHumansRadiology Nuclear Medicine and imaging18F-florbetaben; Alzheimer's disease; Amyloid-PET Imaging; MR-lessAgedRetrospective StudiesPET-CTAniline CompoundsReceiver operating characteristicbusiness.industry18F-florbetaben Alzheimer's disease Amyloid-PET Imaging MR-less Aged Alzheimer Disease Female Humans Image Processing Computer-Assisted Magnetic Resonance Imaging Male Positron Emission Tomography Computed Tomography Retrospective Studies Sensitivity and Specificity Aniline Compounds StilbenesAlzheimer's diseasemedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureMR-lessFemaleNeurology (clinical)Differential diagnosisNuclear medicinebusiness030217 neurology & neurosurgeryPreclinical imagingFrontotemporal dementiaJournal of neuroimaging : official journal of the American Society of Neuroimaging
researchProduct

Oxidative stress in patients with Alzheimer's disease: Effect of extracts of fermented papaya powder

2015

Brain tissue is particularly susceptible to oxidative stress (OS). Increased production of reactive oxygen species (ROS), reduced antioxidant systems, and decreased efficiency in repairing mechanisms have been linked to Alzheimer’s disease (AD). Postmortem studies in AD patients’ brains have shown oxidative damage markers (i.e., lipid peroxidation, protein oxidative damage, and glycoxidation). Fermented papaya (FPP, a product ofCarica papaya Linnfermentation with yeast) is a nutraceutical supplement with favorable effects on immunological, hematological, inflammatory, and OS parameters in chronic/degenerative diseases. We studied 40 patients (age 78.2 ± 1.1 years), 28 AD patients, and 12 co…

MaleAntioxidantSettore MED/09 - Medicina Internamedicine.medical_treatmentReview Articlemedicine.disease_causeAntioxidantsLipid peroxidationchemistry.chemical_compoundchemistry.chemical_classificationAged 80 and overbiologyCaricaBrainBiochemistry8-Hydroxy-2'-DeoxyguanosineFemalePowdersCaricaAlzheimer's diseaseAntioxidantCase-Control StudieReactive Oxygen SpecieOxidation-Reductionlcsh:RB1-214Humanmedicine.medical_specialtyUrinary systemImmunologyPowderAlzheimer DiseaseInternal medicinemedicinelcsh:PathologyHumansAgedDietary SupplementReactive oxygen speciesCase-control studyDeoxyguanosineOxidative StrePlant PreparationCell Biologybiology.organism_classificationmedicine.diseaseAged; Aged 80 and over; Alzheimer Disease; Antioxidants; Brain; Carica; Case-Control Studies; Deoxyguanosine; Dietary Supplements; Female; Fermentation; Humans; Lipid Peroxidation; Male; Oxidation-Reduction; Oxygen; Plant Preparations; Powders; Reactive Oxygen Species; Oxidative Stress; Immunology; Cell BiologyOxygenOxidative StressEndocrinologychemistryCase-Control StudiesDietary SupplementsFermentationPlant PreparationsLipid PeroxidationReactive Oxygen SpeciesOxidative stress
researchProduct

Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation

2007

BACKGROUND: A number of studies associate Alzheimer's disease with APOE polymorphism and alleles which favor the increased expression of immunological mediators such as cytokines or acute phase proteins. We integrated this information to better define risk and determine the relative importance of APOE and immunological mediators. METHODS: We investigated functional gene variants for APOE, IL-10 (3 loci), ACT (2 loci), HMGCR, IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma, and IL-6 found for 260 AD patients and 190 controls enrolled in Northern Italy. A fuzzy latent classification approach, namely grade-of-membership analysis (GoM), was taken to identify extreme pure type risk sets, or profiles. …

MaleApolipoprotein EAgingGenotypeDiseaseBiologyApolipoproteins EAlzheimer DiseaseRisk FactorsGenotypeHumansGenetic Predisposition to DiseaseCognitive declineAlleleGeneAgedAged 80 and overGeneticsPolymorphism GeneticGeneral NeuroscienceAge FactorsAcute-phase proteinGenetic VariationAPOE IL-10 ACT HMGCR IL-1alpha IL-1beta TNF-alpha IFN-gamma IL-6 SNPs Grade of memebership Genetic risk profile Alzheimer's diseaseMiddle AgedUp-RegulationFemaleNeurology (clinical)Gene polymorphismInflammation MediatorsGeriatrics and GerontologyDevelopmental Biology
researchProduct

No association between the cystatin C gene polymorphism and Alzheimer's disease: a case-control study in an Italian population.

2005

Cystatin C is an amyloidogenic protein found together with beta-amyloid in cerebral arteriolar walls of both patients with Alzheimer's Disease (AD) and conghopilic amyloid angiopathy. Several findings implicate cystatin C in the pathogenesis of vascular diseases. Recent genetic association studies proposed cystatin C gene (CST3) as a susceptibility factor for AD, although other reports did not replicate this finding. We conducted a case-control study including 192 probable AD cases and 192 age- and sex-matched controls to test the association between CST3 and AD. Possible interaction between CST3 and age at onset of AD or apolipoprotein E (APOE) was also examined. No significant differences…

MaleApolipoprotein EGenotypeDiseasePathogenesisApolipoproteins EAlzheimer DiseaseGenotypeHumansGenetic Predisposition to DiseaseCystatin CAllele frequencyAllelesAgedGenetic associationAged 80 and overGeneticsGenomic LibraryPolymorphism GeneticbiologyKeywords: Alzheimer’s disease cystatin C apolipoprotein E case-control study polymorphismGeneral NeuroscienceCase-control studyGeneral MedicineMiddle AgedCystatinsPsychiatry and Mental healthClinical PsychologyItalyCystatin CCase-Control StudiesImmunologybiology.proteinSettore MED/26 - NeurologiaFemaleGeriatrics and Gerontology
researchProduct